> CordenPharma Chenôve (FR) completes €35m Phase 2 investment with the inauguration of new small molecule and lipid development, manufacturing and purification facilities. On Monday 2 September, CordenPharma Chenôve Managing Director James Leresche, the site Leadership team (Virginie HILAND, Jocelyne breval, Beatrice LUCAS, André SEMERIE, Sebastien Rose, Charles Leslie DEGILA) and Project Manager Cyril BECAT were joined by CordenPharma CEO Dr. Michael Quirmbach, COO Dr. Lee Newton, Chief Quality & Compliance Officer William Cashin, Chief Commercial Officer Dr. Stephan Haitz and CFO Gary Hughes to inaugurate the completion of the expansion assets for lipids and small molecules at the site. The day began with a breakfast for all employees, followed by executive leadership remarks and an inauguration ceremony in the new synthesis building with key team players on the project. The expansion completed phase 2 of an overall investment started in 2021 after the French Government launched a “Capacity Building” program called AMI (Appel à Manifestation d’Intérêt) to support and boost the industrialization of health products in France. Phase 1, completed in 2022, included the renovation of an R&D laboratory and the addition of several analytical instruments, a GMP mid-scale purification unit, and a newly-hired, focused team of experts. Phase 2 includes the design and construction of a larger GMP manufacturing facility at CordenPharma Chenôve, with a manufacturing concept which increases production capacity to provide customers with multi metric tons of small molecules and lipids using modern chemical reaction, isolation and purification equipment and, in particular, sustainable and innovative Supercritical Fluid Chromatography (SFC) technology, thus reducing supply chain environmental footprint. New expansion features include 6 m3 reactors, agitated filter dryers and centrifuges, the installation of 76 mm and 220 mm SFC technology, and a skid for hydride chemistry, as well as a new warehouse (-20°, 5°C and +20 °C), and storage tank farm extensions for improved storage conditions. The additions not only increase capacity but allow for future pipeline growth. Michael Quirmbach comments, “The completion of this strategic investment will augment our robust lipid and small molecule platforms to support innovators with the complex modalities and sustainable technologies they need for the development and commercialization of LNP-based xRNA and other small molecule therapeutics.” #CordenPharma #francepharma #greenchemistry #purification #lipids #lnps #mrna #pharmamanufacturing #sfc #smallmolecules #pharmaceuticals
Bravo ! Heureux d'avoir participer à l'étude de ce projet, de l'avoir vu se consolider peu à peu et au final se concrétiser.Une belle réalisation.
good morning sir James L Managing Director I am jesudas Victor Mukuri from Hyderabad India have a good experience in pharmaceutical formulation development science and technology covered by all areas and I got a FDA approvals in all sections like manufacturing, qc, formulation development and part of regulatory and logistics Previous i am worked Oman and Malaysia Present I am looking formulation development scientist job and sponcership visa Pls give me a chance I will prove my hard work and ability sir Regards J V Mukuri mjvjesudass@gmail.com
Félicitation à l’ensemble des équipes pour le travail réalisé.
Bravo et toujours disponible si besoin d'échanger !
Impressive growth! 👏🏻
Great news wishing all of you lots of succes and personal development opportunities
Félicitations !
Success with the roll out of your new facility!
Bravo à toute l'équipe !
Group Chief Executive Officer & President at Corden Pharma - A Full-Service CDMO
1wThank you to our team in Chenove for everyone's efforts to bring the new capacity online and a great day on site!